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Abstract
Background:  Loratadine (Claritin®), an over the counter antihistamine in U.S. and UK, is
acceptable for use without adverse side effects by aircrew with mild or moderate allergic or other
situations requiring an antihistamine. Although +Gz (head to foot direction) tolerance testing for
aircrew with loratadine has not been documented in the published literature, it is commonly
accepted that loratadine dose not effect +Gz tolerance. The purpose of this study was to offer and
validate a new evaluation method for +Gz tolerance testing with loratadine by using a near-infrared
spectroscopy (NIRS).
Methods:  A double-blind, placebo-controlled, randomized, crossover protocol was used to
administer 10 mg of loratadine or placebo in nine healthy subjects. The subjects didn't wear anti-G
suit. The +Gz exposure profiles consisted of, in series, a gradual onset ran (0.1 G·sec-1) to the
subject's visual end-point (peripheral light loss) or loss of consciousness (GLOC), and rapid onset
run (1.0 G·sec-1) to the subject's same end-point. In this study, G-level tolerance was defined as the
+Gz level at visual end-point and/or at GLOC. As a subject's G-duration tolerance, we measured
the total time (seconds) during rapid onset run. Otherwise, to confirm the effect of loratadine on
+Gz tolerance, we measured the cerebral NIRS variables (hemoglobin concentration changes and
tissue oxygenation index) as a new quantitative method for +Gz tolerance during a centrifuge
experiments.
Results: No significant differences were observed in +Gz tolerance (+Gz level, duration time and
NIRS variables) between subjects taking loratadine and placebo.
Conclusion: Our results demonstrate that loratadine has no detectable effect on +Gz tolerance
by using a new method with cerebral NIRS variables and the traditional method with +Gz level and
duration time. This study represents the first use of a quantitative parameter such as cerebral NIRS
variables to assess the effects of a drug on acceleration tolerance.
Background
Older first-generation antihistamines, such as diphenhy-
dramine and chlorpheniramine, are unsuitable for use by
aircrew during flight duties due to their well-documented
sedating side effects. Loratadine (Claritin®) is a newer, sec-
ond-generation antihistamine available over-the-counter
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in the US and UK. It has been declared by various civil and
military authorities to be acceptable for use by aircrew
with mild or moderate allergic symptoms or other situa-
tions requiring an antihistamine (e.g. urticaria) due to its
well documented lack of adverse side-effects, including
sedation. Previously, it has been proposed that a single 10
mg dose of loratadine will not effect flying performance
[1]. A single 10 mg dose had no effect on airline pilot per-
formance in flight simulators [2]. Moreover, ingesting 10
mg of loratadine daily did not demonstrate sedative
effects or other impairments of cognitive motor perform-
ance [3]. Recently, a single 5 mg dose of desloratadine (an
active metabolite of loratadine) did not cause sleepiness
nor did it impair the performance of tasks associated with
flying ability [4]. Accordingly, loratadine is advantageous
to aircrew suffering from allergy symptoms due to its lack
of sedation or other central nervous system (CNS) effects
commonly associated with older forms of antihistamine
therapy. For high-performance aircraft pilots, even though
no CNS effects have been demonstrated, loratadine
should be use cautiously and close scrutiny, but no flying
restrictions are necessary provided there are no side-effects
including for ability of +Gz tolerance.
It is commonly accepted loratadine dose not affect +Gz
(head to foot direction) tolerance, although + Gz toler-
ance testing with loratadine that has not been docu-
mented in the published literature [3]. In fact, the air
forces of several nations have treated pilots of high-per-
formance aircraft with loratadine for a decade already. In
general, high-performance aircraft, e.g., fighters and train-
ers need an anti-G straining maneuver and/or +Gz protec-
tion in the military +Gz environment. Consequently, their
ability to tolerate the +Gz acceleration is of major concern
to the military operational communities and a challenge
to acceleration physiologist [5]. More recently, as men-
tioned earlier, loratadine is available in several countries
without a prescription. It is more difficult for people
including medical authority to understand the effects of
self-medication loratadine than prescription loratadine.
Accordingly, a better understanding of the effects of lorat-
adine with published literature medically, pharmacologi-
cally, acceleration physiologically and flight safely, is
important.
In a controlled experimental setting, +Gz tolerance is
examined using a model of +Gz stress (commonly specific
runs in a centrifuge). Centrifuge profiles used in examin-
ing +Gz tolerance may assess +Gz intensity (e.g., peak +Gz
level) or +Gz duration [6]. Thus in assessing relaxed accel-
eration tolerance, these include the assessment of periph-
eral light loss (PLL) or central light loss using a display
system/lights, or the use of 60° peripheral visual loss as an
end point with subject self-report. Other methods of
assessing have also used ear opacity [7], and blood pres-
sure [8,9]. Basically, the ability to tolerate levels of +Gz
exposure is primary a function of adequate blood flow to
the brain [5].
Near-infrared spectroscopy (NIRS) is a non-invasive
method of quantifying changes in cerebral hemodynam-
ics from changes in the absorption of near-infrared light
by oxyhemoglobin (O2Hb) and deoxyhemoglobin
(HHb), and the theory of NIRS is described in detail else-
where [10-14]. The recently developed NIR spatially
resolved spectroscopy has been confirmed to provide
frontal cortical tissue hemoglobin saturation [tissue oxy-
genation index (TOI)] [15,16]. The main use of these tech-
niques in clinical, biomedical and aeromedical research
has focused on the strong signals available from the
hemoglobin chromophores and their relation to cerebral
physiology and pathophysiology [17]. Recently, NIRS is
increasingly used for cerebral hemodynamics and oxygen-
ation changes, and it's a relatively new technique which
allows non-invasive measuring changes in oxygenated
hemoglobin concentration [12,18,19], including first
recorded in a laboratory centrifuge [20,21], saturation of
cerebral vascular space measurements [22], in-flight cere-
bral oxygen status [23,24], a study of the almost loss of
consciousness [25], consciousness monitoring during
high +Gz exposure [26], computer modeling of accelera-
tion effects [27] and electroencephalographic correlation
study concerning Gz-induced loss of consciousness [28].
The purpose of this study was to offer and validate a new
method for +Gz tolerance testing with loratadine by using
a NIRS. Thus, to confirm the effect of loratadine on +Gz
tolerance in healthy subjects during a centrifuge experi-
ments, we measured the cerebral NIRS variables [HHb,
O2Hb, cHb (HHb + O2Hb) and TOI] changes. In addition,
to compare the effect of loratadine on +Gz tolerance, we
also measured +Gz-level tolerance and +Gz-duration tol-
erance as a traditional method [5].
Methods
A double-blind, placebo-controlled, randomized, crosso-
ver protocol was used to administer 10 mg of loratadine
(a powdered tablet) capsule or placebo (lactose) capsule
in 9 volunteer subjects (8 males and 1 female). The mean
age of the 9 subjects was 34.3 years (age 34.3 ± 6.5 yr,
mean ± SD). All subjects were in good health and were
experienced centrifuge riders. None was on any medica-
tion. The intake of drink containing caffeine and smoking
were prohibited from rising in the morning to the end of
the test. The study protocol was approved by the Ethical
Committee of Aeromedical Laboratory, Japan Air Self-
Defense Force (JASDF). All subjects were fully briefed on
the scope of the experiment, and informed consent was
obtained from them before experiment. Each subject's
experiment was measured on two separate days in theDynamic Medicine 2008, 7:3 http://www.dynamic-med.com/content/7/1/3
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same order, at similar time points, and under the same
conditions. Each day the subject took a loratadine capsule
or a matched placebo capsule 90 minutes prior to the cen-
trifuge experiments. On the experiment days, the admin-
istration of medication took place under the supervision
of a member of our laboratory staff to assure mode and
time of proper drug administration. The subjects were
given two trials of the centrifuge exposure, each trial sepa-
rated by a two-week interval. This was to prevent any
effects of repeated trials over short time intervals and to
ensure a complete drug washout had taken place.
The subjects were seated on the human centrifuge at the
JASDF Aeromedical Laboratory Iruma (8-m radius, Shi-
madzu, Kyoto, Japan). The seat had a seat-back to seat-
pan angle of 90° and a seat-back angle of 13° with respect
to the vertical.
The +Gz exposure profiles consisted of, in series, a gradual
onset run (GOR, 0.1 G·sec-1) to the subject's visual end-
point or loss of consciousness (GLOC), and rapid onset
run (ROR, 1.0 G·sec-1) to the subject's same end-point.
The end point was reported by subjects at PLL. A subject
was said to have experienced PLL when the boundary of
her or his visual field subtended an angle less than 60°.
GOR profile was performed without anti-G suit to deter-
mine relaxed tolerance and preceded until the subject's
end-point, after which time the subjects began anti-G
straining maneuvers. And then 5 min rest at 1.0 G after the
GOR, subjects were exposed as a ROR without anti-G suit
to a continuous Gz profile of 10 sec of 1.4 G, then 10 sec
of 4 G, back to 60 sec of 1.4 G, then 10 sec of 5 G, back to
60 sec of 1.4 G, then 10 sec of 6 G, back to 60 sec of 1.4
G, etc., until the subject reports end-point, GLOC or
fatigue (Figure 1). As noted above, the subjects were not
provided with G suits, but protected themselves until end-
point and/or GLOC by voluntary G protective maneuvers
such as muscle straining and L-1 maneuvers.
G-level tolerance was defined as the +Gz level at end-point
or at GLOC. Thus we measured relaxed G-level tolerance
(which includes involuntary G protection) and straining
G-level tolerance (which includes protection afforded by
executing the anti-G straining maneuver) during the GOR
centrifuge profile. On the other hand, duration time for
voluntary fatigue or visual loss has been validated as a
reproducible end point which represents an individual's
ROR G-duration tolerance. As a duration time, thus we
measured the total time (seconds) from the start of ROR
at 1.4 G to the subject's end-point above 1.4 G (Figure 1).
Additionally, to confirm the effect of loratadine on +Gz
tolerance in healthy subjects during a centrifuge experi-
ments, we measured the cerebral HHb, O2Hb, cHb and
TOI changes. We used a NIRS system (NIRO-150G;
Hamamatsu Photonics K.K., Japan) at three wavelengths
(775, 830, and 850 nm). The optical pathlength factor
was 5.93 [29]. After cleaning of the subject's forehead with
alcohol, the optodes were carefully fixed, using flexible
and adhesive fixation pad and double-faced adhesive
tape. A light emitter (emitting optode) and a light detector
(collecting optode) were placed with a distance of 4 cm
between them on the right forehead of the subjects. Each
probe was protected from ambient light by surgical tape.
Data were collected with sampling intervals of 0.167 sec.
A baseline correction was performed about 20 sec before
centrifuge experiments. We analyzed the changes in O2Hb
by subtracting the mean baseline values (before the cen-
trifuge experiment) from the end point values in each +Gz
exposure. The mean changes of HHb (ΔHHb), O2Hb
(ΔO2Hb), cHb (ΔcHb) and ΔTOI relative to baseline for
each +Gz exposure were calculated for all subjects. The
electrocardiogram and heart rate of the subjects were also
monitored throughout the experiment. In this study, one
of nine subjects experienced GLOC at the ROR profile, the
subject was quickly removed from the high +Gz environ-
ment. Additional centrifuge run of the subject was not car-
ried out within two weeks.
Wilcoxon singed-rank test were used to determine the sig-
nificance of the levels of the end-point and NIRS variable
changes for the subjects administrated placebo and lorat-
adine during the centrifuge run. Results were expressed as
the mean ± standard deviation (SD) at each sampling
period for all subjects. A p-value of <0.05 was considered
statistically significant in all experiments.
Results
G tolerances are listed as mean (± SD). G-level tolerances
during relaxed GOR profile were 3.64 ± 0.72 on lorata-
dine and 3.93 ± 0.43 on placebo (Figure 2). The straining
G-level tolerances during GOR profile were 5.86 ± 0.78 on
loratadine and 5.88 ± 0.48 on placebo (Figure 2). G-dura-
tion tolerances during ROR profile were 28.1 ± 19.5 (sec)
on loratadine and 28.4 ± 19.0 (sec) on placebo (Figure 3).
NIRS variables at end point between placebo and lorata-
dine during +Gz exposure with GOR and ROR are shown
in Table 1. No significant differences observed in all NIRS
variables between subjects taking placebo and loratadine
during +Gz exposure with GOR and ROR.
Discussion
Previously, after single oral administration of loratadine
(20 mg), mean maximum plasma concentration was
found for loratadine at 1.2 hours and for desloratadine
(an active metabolite of loratadine) at 1.5 hours, respec-
tively [30]. Then in this study, the subject took loratadine
capsule or a matched placebo capsule for 90 min prior to
the centrifuge experiments.Dynamic Medicine 2008, 7:3 http://www.dynamic-med.com/content/7/1/3
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Gz exposure profile Figure 1
Gz exposure profile. GOR: gradual onset run, ROR: rapid onset run, PLL: peripheral light loss, AGSM: anti-G straining 
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As a rule, the term G tolerance was coined to include the
magnitude (i.e., level) of the +Gz stressor and the dura-
tion of exposure to the +Gz stressor [31]. The traditional
method used to determine relaxed G-level tolerance is the
symptom loss of vision in a relaxed, upright-seated sub-
ject at a specific of G exposure [5]. Otherwise, G-duration
tolerance is the length of time in seconds that a subject can
continue to maintain vision, usually performing a simple
task while exposed to a repeating predetermined G profile
that continues until the G exposure is stopped by the sub-
ject because of fatigue [5]. In this study, during the GOR
centrifuge profile, no significant difference was found
between the loratadine and placebo groups in either
relaxed or straining G-tolerance (Figure 2). Moreover, no
significant difference was observed in G-duration toler-
ance between the 2 groups as well (Figure 3). As stated
above, our results with the traditional method suggest
that there were not significant effects of loratadine on tol-
erance to + Gz acceleration.
In this study, the effect of loratadine on +Gz tolerance was
also assessed quantitatively using NIRS. High +Gz expo-
sure is believed to induce cerebral ischemia and perhaps
cause a disproportionately greater fall in O2Hb tissue lev-
els than those found at 1 Gz [5,24,32,33]. A combination
of these effects of G-forces is probably the predominant
reasons for peripheral visual field, visual greyout or black-
out, and GLOC. Moreover, it is also believed that the abil-
ity to tolerate +Gz exposure is primarily a function of
adequate blood flow to the brain. Consequently, symp-
toms that relate to inadequate blood flow to the head are
used as a measure of +G-level tolerance [5].
In general, the sum of the concentration of O2Hb and
HHb (cHb = O2Hb + HHb) generally provides a measure
Table 1: NIRS variables at end point between placebo and loratadine during +Gz exposure with GOR and ROR.
GOR ROR
NIRS Variable Relaxed Straining Straining
Placebo Loratadine Placebo Loratadine Placebo Loratadine
ΔO2Hb (μmol·L-1) -10.5 ± 5.6 -11.1 ± 5.7 -17.4 ± 8.1 -16.9 ± 7.4 -14.7 ± 7.2 -15.0 ± 6.4
ΔHHb (μmol·L-1) 0.5 ± 2.4 -0.1 ± 3.4 2.8 ± 1.2 1.4 ± 4.6 0.7 ± 3.0 1.9 ± 3.7
ΔcHb (μmol·L-1) -11.3 ± 6.8 -12.8 ± 8.6 -13.2 ± 6.8 -15.5 ± 12.6 -13.6 ± 7.0 -12.0 ± 7.6
TOI% 67.6 ± 4.5 70.2 ± 6.4 64.8 ± 3.7 67.2 ± 6.9 63.5 ± 4.8 66.3 ± 5.7
Baseline 72.4 ± 4.7 73.6 ± 5.1 72.2 ± 4.9 73.7 ± 4.7
ΔTOI% -4.8 ± 2.5 -3.3 ± 3.2 -7.6 ± 2.2 -6.4 ± 4.0 -8.8 ± 1.5 -7.4 ± 3.1
Values are means ± standard deviation. NIRS: near-infrared spectroscopy, GOR: gradual onset run, ROR: rapid onset run, O2Hb: oxygenated 
hemoglobin, HHb: deoxygenated hemoglobin, cHb: O2Hb + HHb, TOI: tissue oxygenation index, Δ: change.
G-level tolerance on the GOR profile Figure 2
G-level tolerance on the GOR profile. Data are pre-
sented as mean ± standard deviation, n = 9. GOR: gradual 
onset run.
G-duration tolerance on the ROR profile Figure 3
G-duration tolerance on the ROR profile. Data are pre-
sented as mean ± standard deviation, n = 9. ROR: rapid onset 
run.Dynamic Medicine 2008, 7:3 http://www.dynamic-med.com/content/7/1/3
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of the cerebral blood volume, whereas the individual con-
centrations of the two forms of hemoglobin are the result
of the interplay between physiological parameters such as
regional blood volume and blood flow [34]. Otherwise,
functional magnetic resonance imaging (fMRI)-NIRS or
positron emission tomography-NIRS simultaneous meas-
urement studies have reported that O2Hb is strongly cor-
related with the fMRI signal and regional cerebral blood
flow [35-37]. Moreover, a previous in-flight study in an F-
15 aircraft, where cerebral oxygen status (O2Hb, cHb and
TOI) was monitored showed that the effect of +Gz accel-
eration was to simultaneously lower blood flow in a mir-
ror image fashion to the applied acceleration [24]. This
NIRS technology has matured for continuous monitoring
of in-flight cerebral oxygen status under various field con-
ditions. However, in-flight study should design preserved
flight safety by collecting data on the pilots.
As described above, +Gz exposure is believed to induce
cerebral ischemia and perhaps cause a greater fall in cere-
bral O2Hb. Recently, our laboratory study demonstrated
the TOI to be a useful variable to evaluate the effect of the
anti-G protection system [19]. Accordingly, this accepted
hypothesis and based on previous centrifuge experiments
including our laboratory study, we believe the measuring
of cerebral hemoglobin concentration changes (ΔHHb,
ΔO2Hb and ΔcHb) and TOI changes during +Gz exposure
are an applicable and a new method to investigate the
effect of loratadine on +Gz tolerance.
In all NIRS variables, as results, no statistically significant
differences were found between the subjects on loratadine
and placebo (Table 1). In this study including previous
our study, HHb increases above its base level during Gz
exposure, while cHb and O2Hb incurred greater degreases
from its base level. Decreases in cerebral cortex oxygen sat-
uration or increases of HHb during +Gz exposure might
be the result of arterial and venous left-right shunt and the
hydrostatic effect of +Gz. Both O2Hb and cHb are sensi-
tive indices in cerebral oxygen saturation increment
induced by anti-G maneuver and the anti-G system
[23,24]. Kobayashi et al. also reported that the ΔO2Hb
was negatively correlated with +Gz during aerial combat
maneuvering [24]. As noted above, the TOI is useful to
evaluate the effect of anti-G protection system [19]. In this
study, ΔO2Hb/ΔcHb and/or ΔTOI that we observed with
great changes in NIRS measurements were considered the
quantitative parameter such as +Gz acceleration tolerance.
Unfortunately, our sample size was limited (i.e., nine sub-
jects). However, we believe this study represents the first
use of a quantitative parameter such as ΔO2Hb/ΔcHb and/
or ΔTOI to assess the effects of loratadine on acceleration
tolerance. NIRS represents a major break-through in
research and development.
Conclusion
No significant differences were observed in +Gz tolerance
(+Gz level, duration time and NIRS variables) between
subjects taking loratadine and placebo. Our results dem-
onstrate that loratadine has no detectable effect on +Gz
tolerance by using a new NIRS method with ΔO2Hb/ΔcHb
and/or ΔTOI and the traditional method with +Gz level
and duration time. This study represents the first use of a
quantitative parameter such as ΔO2Hb/ΔcHb and/or TOI
to assess the effects of a drug on acceleration tolerance.
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